Kilitch Drugs (India) (NSE:KILITCH) Long-Term Debt: ₹586 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:KILITCH Kilitch Drugs (India) Ltd NSE:KILITCH
84 GF Score
Price ₹178.18
GF Value ₹227.12
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Kilitch Drugs (India) Long-Term Debt?

Kilitch Drugs (India) NSE:KILITCH -2.38% 84 Long-Term Debt is ₹586 Mil as of Mar. 2026. GuruFocus rates NSE:KILITCH with a GF Score™ of 84/100 and a GF Value™ of ₹227.12 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Kilitch Drugs (India)'s Long-Term Debt for the quarter that ended in Mar. 2026 was ₹586 Mil.

Kilitch Drugs (India)'s quarterly Long-Term Debt declined from Sep. 2025 (₹513 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹586 Mil).

Kilitch Drugs (India)'s annual Long-Term Debt increased from Mar. 2024 (₹0 Mil) to Mar. 2025 (₹278 Mil) and increased from Mar. 2025 (₹278 Mil) to Mar. 2026 (₹586 Mil).

Kilitch Drugs (India)  (NSE:KILITCH) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Kilitch Drugs (India) Long-Term Debt Related Terms

Kilitch Drugs (India) Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Kilitch Drugs (India)'s Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kilitch Drugs (India) Long-Term Debt Chart

Kilitch Drugs (India) Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 277.70 586.04

Kilitch Drugs (India) Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 277.70 0.00 513.41 0.00 586.04
NSE:KILITCH
84GF Score
Kilitch Drugs (India) Ltd NSE:KILITCH
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of ₹586 Mil mean?
Kilitch Drugs (India) (NSE:KILITCH) has a Long-Term Debt of ₹586 Mil as of Mar. 2026.
Is Kilitch Drugs (India)'s Long-Term Debt too high?
Kilitch Drugs (India)'s current Long-Term Debt is ₹586 Mil. Overall, Kilitch Drugs (India) has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kilitch Drugs (India)'s Long-Term Debt compare to ZTS and UTHR?
Kilitch Drugs (India)'s Long-Term Debt of ₹586 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Kilitch Drugs (India)'s current Long-Term Debt is ₹586 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kilitch Drugs (India) stock overvalued right now?
Based on GuruFocus' analysis, Kilitch Drugs (India) (NSE:KILITCH) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹227.12, compared to a current price of ₹178.18 — trading 21.5% below its estimated fair value. The current Long-Term Debt is ₹586 Mil. Kilitch Drugs (India)'s overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Kilitch Drugs (India) (NSE:KILITCH), the current Long-Term Debt is ₹586 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kilitch Drugs (India) (NSE:KILITCH) Overvalued in 2026?

Based on GuruFocus' analysis, Kilitch Drugs (India) stock appears to be undervalued. The current stock price of ₹178.18 is trading 21.5% below its estimated GF Value™ of ₹227.12. GuruFocus considers Kilitch Drugs (India) to be Modestly Undervalued.

Key valuation signals for NSE:KILITCH:

  • Long-Term Debt: ₹586 Mil
  • GF Value™: ₹227.12 vs. price of ₹178.18 (21.5% below fair value)
  • GF Score™: 84/100 with 4 warning signs

No single metric tells the full story. See the NSE:KILITCH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kilitch Drugs (India) Business Description

Other Exchanges 524500:India
Address Waman Tukaram Patil Marg, 37/39, Ujagar Industrial Estate, Deonar, Mumbai, MH, IND, 400 088
Kilitch Drugs (India) Ltd is an India-based pharmaceutical company. It is engaged in operation and management of Pharmaceutical Products. The company offers parenteral and nasal products, oral formulations, effervescent tablets, nutritional products, medical devices, and cosmetic and health products. Some of the products offered by the company are Roipar, Roivit, PH-7, C-Seal, SRO kit, 9-VIT, and HPURE. The company has one reportable segment, which is the development and operations of the Pharmaceutical business.
84GF Score

Get the complete analysis for NSE:KILITCH

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹178.18
Price
₹227.12
GF Value